Skip to main content

Month: August 2024

Fairfax Announces Acquisition of Additional Ensign Energy Services Inc. Common Shares

TORONTO, Aug. 14, 2024 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) announces that it has acquired, through its insurance company subsidiaries, 271,100 common shares (“Common Shares”) of Ensign Energy Services Inc. (“Ensign”) at a price of C$2.4238 per Common Share for an aggregate purchase price of approximately C$657,092.18 through the facilities of the Toronto Stock Exchange (the “Share Purchase”). The Share Purchase represents approximately 0.15% of the issued and outstanding Common Shares of Ensign and brings Fairfax’s total holdings, through its insurance subsidiaries, of such securities to 33,406,386 Common Shares (or approximately 18.19% of all Common Shares). Immediately prior to the Share Purchase, Fairfax, through its insurance company subsidiaries, beneficially owned and controlled...

Continue reading

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

– Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH’s distribution footprint to include Cencora, Inc. as a specialty distributor – – Announces positive preliminary topline results of Phase 2 clinical study of VP-315 for the treatment of patients with basal cell carcinoma – – Continues to progress preparation for global Phase 3 Common Warts trial with initiation expected in 1H 2025 – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2024. “Verrica continued to make steady...

Continue reading

Form 8.3 – [IQGEO GROUP PLC – 13 08 2024] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary Clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree IQGEO GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Form 8.3 – [KEYWORDS STUDIOS PLC – 13 08 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree KEYWORDS STUDIOS PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Microbix Reports Continued Strong Results for Q3 Fiscal 2024

Revenues of $5.1 million and Net Income of $0.25 million MISSISSAUGA, Ontario, Aug. 14, 2024 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and first nine months of fiscal 2024 ended June 30, 2024 (“Q3” and “YTD”) with strong revenues, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices businesses and resulting in material net income for Q3 and YTD. Management DiscussionResults for Q3 show robust growth in sales of Microbix’s test ingredients (“Antigens”) and test quality assessment products (“QAPs™”), which were collectively up by 20% versus prior year. The resulting revenues of C$ 5.1 million led to net earnings and continue to set the stage...

Continue reading

Marex Group plc announces 2024 Interim Results

NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) — Marex Group plc (‘Marex’ or the ‘Group’; Nasdaq: MRX), a diversified global financial services platform, announces strong results for the six months ended 30 June 2024, and a positive outlook for the full year. H1 2024 HighlightsFinancial Highlights: ($m) 3 months ended 30 June 2024   3 months ended 31 March 2024   Change1   6 months ended 30 June 2024   6 months ended 30 June 2023   Change1Reported                      Revenue 422.1   365.8   15%   787.9   622.4   27%Profit Before Tax 80.1   58.9   36%   139.0   109.5   27%Profit Before Tax Margin (%) 19%   16%   300bps   18%   18%   — bpsProfit After Tax 59.3   43.6   36%   102.9   80.8   27%Return on Equity (%) 29%   23%   600bps   25%   23%   200 bpsBasic Earnings per Share ($)2 0.81   0.60   35%   1.41   1.13   25%Diluted...

Continue reading

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

CLEVELAND, Aug. 14, 2024 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric Crombez, MD as new independent members to its Board of Directors. Dr. Zeiher brings more than 20 years of drug development experience where, in various roles, he oversaw the approval of 15 new treatments that addressed unmet needs in serious diseases with few to no treatment options. Dr. Crombez currently serves as Chief Medical Officer of Ultragenyx Pharmaceutical Inc. and brings extensive expertise in the development and execution of clinical development programs for rare genetic disorders. Michael Amoroso, Chairman of Abeona’s Board of Directors, said, “We are delighted to welcome both Bernie Zeiher and Eric Crombez to our Board during this important period in Abeona’s...

Continue reading

Prime Drink Group Corp. Enters Into a Final Share Purchase Agreement to Acquire Triani Canada Inc.

MONTREAL, Aug. 14, 2024 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it has entered into a second amended and restated share purchase agreement dated August 7, 2024 (the “Amended and Restated SPA”) with 9296-0186 Québec Inc. (“9296”), the shareholders of 9296, and Angelpart Ventures Inc. (collectively, the “Vendors”), amending, restating, and replacing the SPA (as defined below) to revise, among other things, the purchase price, the bonus consideration and to remove any reference to the proposed share consolidation of Prime. As described in the press releases dated May 15, 2024 and May 22, 2024, the Company entered into a share purchase agreement dated May 14, 2024, which was amended and restated on May 21, 2024 (the “SPA”), whereby the Company will acquire all of the issued and...

Continue reading

FitLife Brands Announces Second Quarter 2024 Results

Omaha, Aug. 14, 2024 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the second quarter ended June 30, 2024. Highlights for the second quarter ended June 30, 2024 include:Total revenue was $16.9 million, an increase of 15% compared to the second quarter of 2023.   Online sales were $11.2 million, representing 66% of total revenue and an increase of 13% compared to the second quarter of 2023. Gross margin was 44.8% compared to 40.4% during the second quarter of 2023. Net income was $2.6 million compared to $2.0 million during the second quarter of 2023. Basic earnings per share and diluted earnings per share were $0.57 and $0.53, respectively, compared to $0.44 and $0.40...

Continue reading

CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the second quarter and six months ended June 30, 2024 and provided an update on its business. Recent Corporate Highlights:CorMedix today reports our initial partial quarter of sales since DefenCath’s inpatient launch on April 15th. The Company reported net sales of $0.8 million for the second quarter, which primarily represents trade stocking for inpatient facilities. The company has started to see pull-through of units to inpatient facilities in the third quarter, and expects that pace to accelerate over the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.